Drug intelligence / Profile preview

bupivacaine + levobupivacaine

Development stage
Unknown
Lead developer
UCB
Modality
Small Molecules
Administration
Epidural, Intrathecal, Perineural, Local Infiltration
01

Overview

**Bupivacaine + levobupivacaine** denotes a putative combination of two long-acting amino-amide local anesthetics. Bupivacaine is the racemic drug substance, whereas levobupivacaine is its single S-enantiomer; consequently, this combination would add levobupivacaine to a preparation already containing the S-enantiomer as part of racemic bupivacaine. Both agents reversibly and use-dependently inhibit voltage-gated sodium channels in peripheral nerves, suppressing action-potential initiation and propagation to produce local or regional anesthesia and analgesia. No specific marketed, registered clinical-development, or standardized co-formulated product containing exactly these two active ingredients was identified.

Other names
bupivacain + levobupivacaine
02

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)KCNH2 (Voltage-gated potassium channel subfamily H member 2)SCN10A (Sodium channel protein type X alpha subunit)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on bupivacaine + levobupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + levobupivacaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call